Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | FSHR | P23945 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 4/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29988590 | 1.00 | GSK3B (0.46) | GSK3BMAPTTSHRFSHRDYRK1A | |
| SCHEMBL23612055 | 0.83 | GSK3B (0.47) | GSK3BMAPTGSK3AKIF18APIK3C3 | |
| SCHEMBL29988330 | 0.80 | TSHR (0.43) | GSK3BMAPTTSHRFSHRDYRK1A | |
| SCHEMBL26507319 | 0.80 | TSHR (0.43) | GSK3BMAPTTSHRFSHRDYRK1A | |
| SCHEMBL29988807 | 0.79 | GSK3B (0.40) | GSK3BTSHRFSHRDYRK1ACDK9 | |
| SCHEMBL23612124 | 0.79 | GSK3B (0.40) | GSK3BTSHRFSHRDYRK1ACDK9 | |
| SCHEMBL18308988 | 0.77 | GSK3B (0.47) | GSK3BDYRK1ACDK9RORCMAPK1 | |
| SCHEMBL28641960 | 0.76 | GSK3B (0.45) | GSK3BDYRK1ACDK9RORCKCNQ3 | |
| SCHEMBL23611974 | 0.76 | GSK3B (0.46) | GSK3BMAPTGSK3A | |
| SCHEMBL30020864 | 0.76 | GSK3B (0.46) | GSK3BMAPTGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| CN-115348957-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115279770-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2021138434-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
| WO-2021138419-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC, (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | GSK3B 487/4885MAPT 3027/4885TSHR 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.